Business Context and Reporting Period
This Form 8-K Current Report was filed by CytoSorbents Corporation on June 12, 2019. The report details corporate governance actions taken at the 2019 Annual Meeting of Stockholders held on June 4, 2019, and the subsequent filing of a Restated Charter with the State of Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate structural changes rather than financial performance.
Material Changes
- Authorized Common Stock: Increased from 50,000,000 shares to 100,000,000 shares.
- Authorized Capital Stock: Increased from 55,000,000 shares to 105,000,000 shares.
- Legal Documentation: The Second Amended and Restated Certificate of Incorporation was filed with the Delaware Secretary of State on June 12, 2019.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is a procedural report regarding the amendment of the Company's Articles of Incorporation.
Investor Verification Checklist
- Verify the effective date of the Second Amended and Restated Certificate of Incorporation (June 12, 2019).
- Confirm the new total authorized share counts (100M common, 105M total capital) against the company's capitalization table.
- Review the full text of the Restated Charter (Exhibit 3.1) for any additional amendments not summarized in this report.